EIA
VRTX icon

Edgemoor Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Edgemoor Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3M Sell
55,020
-395
-0.7% -$175K 1.86% 14
2026
Q1 		$24.7M Buy
55,415
+576
+1% +$269K 1.95% 13
2025
Q4 		$24.9M Sell
54,839
-355
-0.6% -$153K 1.93% 13
2025
Q3 		$21.6M Sell
55,194
-830
-1% -$347K 1.67% 15
2025
Q2 		$24.9M Sell
56,024
-772
-1% -$356K 2.15% 13
2025
Q1 		$27.5M Sell
56,796
-301
-0.5% -$140K 2.53% 10
2024
Q4 		$23M Buy
57,097
+92
+0.2% +$42.6K 2.03% 14
2024
Q3 		$26.5M Buy
57,005
+123
+0.2% +$59.1K 2.31% 13
2024
Q2 		$26.7M Buy
56,882
+350
+0.6% +$152K 2.48% 13
2024
Q1 		$23.6M Buy
56,532
+150
+0.3% +$63.4K 2.23% 13
2023
Q4 		$22.9M Buy
56,382
+544
+1% +$201K 2.4% 10
2023
Q3 		$19.4M Buy
55,838
+254
+0.5% +$88.8K 2.3% 11
2023
Q2 		$19.6M Sell
55,584
-279
-0.5% -$94K 2.21% 10
2023
Q1 		$17.6M Buy
55,863
+343
+0.6% +$103K 2.14% 10
2022
Q4 		$16M Sell
55,520
-310
-0.6% -$94.5K 2.01% 10
2022
Q3 		$16.2M Buy
55,830
+799
+1% +$230K 2.15% 10
2022
Q2 		$15.5M Sell
55,031
-122
-0.2% -$32.7K 1.95% 12
2022
Q1 		$14.4M Buy
55,153
+10,825
+24% +$2.57M 1.52% 15
2021
Q4 		$9.73M Buy
44,328
+9,654
+28% +$1.88M 1% 35
2021
Q3 		$6.29M Buy
+34,674
New +$6.77M 0.72% 43

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Edgemoor Investment Advisors's VRTX Position: Q2 2026 in Review

Edgemoor Investment Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.71% in Q2 2026, selling an estimated $175K and leaving 55,020 shares worth $27.3M. The position accounts for 1.86% of the portfolio, ranked #14.

Edgemoor Investment Advisors first reported a position in VRTX in Q3 2021 and has held it in 20 quarters since. The position peaked at $27.5M in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Edgemoor Investment Advisors held 55,020 shares of Vertex Pharmaceuticals worth $27.3M as of Q2 2026.
  • Edgemoor Investment Advisors sold 395 Vertex Pharmaceuticals shares in Q2 2026, an estimated $175K.
  • Vertex Pharmaceuticals made up 1.86% of Edgemoor Investment Advisors's portfolio in Q2 2026, its #14 holding.
  • Edgemoor Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Edgemoor Investment Advisors's Vertex Pharmaceuticals position peaked at $27.5M in Q1 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Edgemoor Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.